GSK announces positive results from phase III severe asthma trials …
May 21, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and adolescents with severe asthma with type 2 inflammation characterised by blood eosinophil count. 1,2 Both SWIFT-1 and SWIFT-2 …
GSK announces positive phase III results from ANCHOR trials for ...
Oct 14, 2024 · Depemokimab’s extended half-life, high potency and high binding affinity for IL-5 means it has the potential to provide sustained inhibition of broad inflammatory functions with dosing once every six-months. The phase III programme includes evaluation of depemokimab in other IL-5 mediated diseases.
Depemokimab accepted for review by the European Medicines Agency ... - GSK
Jan 28, 2025 · Depemokimab, a monoclonal antibody that targets interleukin-5 (IL-5), is the first ultra-long-acting biologic to be evaluated in phase III trials and be accepted for regulatory review for use in these conditions. 1 Depemokimab's extended half-life, high-binding affinity and potency, support six month (26 week) dosing regimens based on results ...
Twice-Yearly Depemokimab in Severe Asthma with an …
Sep 9, 2024 · Depemokimab is an ultra-long-acting biologic therapy with enhanced binding affinity for interleukin-5 that may enable effective 6-month dosing intervals.
GSK reports data from Phase III trials of severe asthma treatment
Sep 10, 2024 · UK-based pharmaceutical company GSK has announced results from two Phase III clinical trials of depemokimab in patients with severe asthma characterised by elevated blood eosinophil counts, a marker of type 2 inflammation.
Twice-Yearly Depemokimab in Severe Asthma with an …
Sep 9, 2024 · Depemokimab reduced the annualized rate of exacerbations among patients with severe asthma with an eosinophilic phenotype. (Funded by GSK; SWIFT-1 and SWIFT-2 ClinicalTrials.gov numbers, NCT04719832 and NCT04718103.).
GSK boasts win for depemokimab in asthma trials - Clinical Trials …
May 21, 2024 · GSK has announced positive data from two Phase III trials of its asthma candidate depemokimab. The pharma giant announced the drug met primary endpoints in both the SWIFT-1 (NCT04719832) and SWIFT-2 (NCT4718103) trials of a reduction in exacerbations (asthma attacks) over 52 weeks.
GSK’s twice-yearly asthma drug clears two phase 3 trials
6 days ago · The company says new IL-5 inhibitor depemokimab (formerly GSK3511294) has the potential to become the first ultra-long-acting biologic for severe asthma with a six-monthly dosing schedule.
GSK's long-acting asthma drug halved attacks in phase 3
Sep 9, 2024 · GSK is continuing to tout depemokimab as one of its 12 potential blockbuster launches of the coming years, with the asthma drug expected to generate peak-year sales of 3 billion pounds sterling...
GSK’s Depemokimab Significantly Reduces Asthma Exacerbations
Sep 10, 2024 · Results from a pooled analysis of the Phase III SWIFT-1 and SWIFT-2 trials demonstrated that GSK’s depemokimab, a biologic targeting severe asthma with type 2 inflammation, significantly reduces exacerbations of the condition.